Publication: Magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: A systematic review and meta-analysis
No Thumbnail Available
Date
2021
Authors
Mustafa, Mohamad Azzlee
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Study objective Magnesium sulfate has been used in exacerbation of chronic obstructive pulmonary disease (COPD) with mixed results, but its application was not mentioned in Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019. The aim of our review is to assess the effectiveness of magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease. Methods We searched via CENTRAL, Medline, Embase and trial registries for relevant randomised controlled trials. Screening of full texts, evaluation for eligibility and data extraction were done by two independent reviewers. Risk ratios and mean differences were estimated using the random-effects model with 95% confidence intervals. Results We included six trials involving 395 patients. Three modes of administration of magnesium sulfate reported were nebulized, intravenous and a combination of both modes. While some individual studies stated improvement in lung function indices favoring the intervention group, none of the pooled results demonstrate a remarkable clinical benefit as measured by FEV1 predicted percentage, FEV1 volume and peak expiratory flow rate. Subgroup analysis based on the timing of measurement and method of magnesium sulfate administration failed to show any significant difference. Evaluation of secondary outcomes concluded that addition of magnesium sulfate to standard therapy does not produce significant clinical effect in term of length of hospital stay, hospital admission, intensive care unit admission, ventilation requirement, mortality rate, oxygen saturation and adverse effects. Conclusions The findings of six studies conducted in this review did not provide clear evidence of benefits to endorse magnesium sulfate use during COPD exacerbation and consequently, the evidence available to date is insufficient to guide the change in clinical practice. The current meta‐analysis summarized data from a small number of studies involving relatively few patients. Further larger and well-designed randomised controlled trials are required to determine the effectiveness of magnesium sulfate in exacerbation of COPD.
Description
Keywords
-